Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein
Publikation: Beitrag in Fachzeitschrift › Forschungsartikel › Beigetragen › Begutachtung
Beitragende
Abstract
The development of T-cell-based immunotherapies of cancer largely depends on the availability of tumour-associated antigens capable of eliciting tumour-directed cytotoxic T-cell responses. In prostate cancer, the number of antigens defined as suitable targets of cytotoxic T lymphocytes (CTLs) is still limited. Recently, prostein was identified as a transmembrane protein that is highly restricted to prostate tissues. In our study, prostein transcripts were found to be abundant in both malignant and nonmalignant prostate tissue samples. To identify immunogenic CD8+ T-cell epitopes, human leucocyte antigen-A*0201-binding peptides were selected from the amino-acid sequence of prostein and were used for the in vitro stimulation of CD8+ T lymphocytes. Specific CTLs were raised against the prostein-derived peptide CLAAGITYV that were capable of lysing prostate cancer cells, indicating that this peptide is naturally generated by tumour cells. Our data suggest that prostein is a suitable candidate to be included in a T-cell-based immunotherapy of prostate cancer.
Details
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 1034-1040 |
Seitenumfang | 7 |
Fachzeitschrift | British journal of cancer |
Jahrgang | 90 |
Ausgabenummer | 5 |
Publikationsstatus | Veröffentlicht - 8 März 2004 |
Peer-Review-Status | Ja |
Externe IDs
PubMed | 14997204 |
---|
Schlagworte
Ziele für nachhaltige Entwicklung
ASJC Scopus Sachgebiete
Schlagwörter
- Dendritic cells, Immunotherapy, Prostein, T cells, Tumour antigen